Open AccessProtectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia
Author(s) -
Yetty Movieta Nency,
Farid Agung Rahmadi,
- Mulyono,
Dimas Tri Anantyo,
Nur Farhanah,
Rebriarina Hapsari,
Helmia Farida,
Udadi Sadhana,
Tri Nur Kristina,
Achmad Zulfa Juniarto,
Mita Puspita,
Rini Mulia Sari,
Novilia Sjafri Bachtıar
Publication year - 2022
Publication title -
clinical and experimental vaccine research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.958
H-Index - 11
eISSN - 2287-366X
pISSN - 2287-3651
DOI - 10.7774/cevr.2022.11.1.43
Subject(s) - medicine , vaccination , immunogenicity , hepatitis b , hepatitis a vaccine , hepatitis a , adverse effect , hepatitis b vaccine , immunization , virology , serology , hepatitis , immunology , hepatitis b virus , hbsag , antibody , virus
Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both the national immunization program and global needs. To keep the sustainability of the vaccine, a new bulk is needed to be made available. This study aims to evaluate the immunogenicity and safety of Bio Farma newly formulated recombinant hepatitis B vaccines, which came from different sources of bulk, compared to the already registered hepatitis B vaccine.